“certainly will be supportive of our twenty-seven and beyond, you know, kind of range that I've talked about where we'll be at the midpoint or above in that two to four percent guidance.”

In context

“investing in durable and, you know, plans are designed around care management, enabling care management, we've made meaningful benefit adjustments. So all the kind of levers that are in our control related to the product design, operational, cost efficiency is absolutely something that we will continue to drive. We are partnered incredibly closely with Sandeep and the team at Optum around different use cases of, you know, how AI can not only drive efficiency, but also help inform the forecast in terms of both kinda how we respond to headwinds or challenges as well as kinda how we identify solutions and can bring those to stakeholders. Think about kind of all of those, you know, really in the mix as we think about opportunities to, you know, leverage those efficiencies, drive margins, and certainly will be supportive of our twenty-seven and beyond, you know, kind of range that I've talked about where we'll be at the midpoint or above in that two to four percent guidance. Stephen Hensley: Okay. We have time for one more question. So please, next. Operator: And our last question comes from Ben Hendericks with RBC Capital Markets. Ben Hendericks: Great. Thank you for squeezing me in. In light of your business line review and your reorientation of some businesses and balancing that with a sustained commitment to value-based care, I'm wondering if there's any changes to how you're thinking about the breadth and scale of care capabilities that you want to add to support VBC. And specifically, I'm thinking about kind of commitment to assets like the pending meta acquisition and the expected closing there. Thanks. Stephen Hemsley: Sure. Do you want to comment on the MedAssist and then Patrick maybe comment about kind of the broader question there? John Rex: Yeah.”